GLP-1 clinical trials in Rhode Island: 7 recruiting now

7 GLP-1 clinical trials are recruiting at 7 sites in 4 cities across Rhode Island. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Rhode Island

1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

   Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

   A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

   Who can join. Adults 40 to 80, have type 2 diabetes.

   1 site in Rhode Island

   • Family Care Center at Kent Hospital, Pawtucket. 401-921-9066

2. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

   Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

   1 site in Rhode Island

   • University Gastroenterology, Providence. 401-421-8800

3. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

   Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

   1 site in Rhode Island

   • University Gastroenterology, Providence. 401-421-8800

4. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

   A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

   1 site in Rhode Island

   • University Gastroenterology, Providence

5. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

   Phase 3. Run by Kailera. Registry number NCT07284979.

   A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

   Who can join. Adults 18+, have obesity, BMI 35+.

   1 site in Rhode Island

   • Kailera Clinical Site, East Greenwich

6. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

   Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

   A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

   Who can join. Adults 18+, have obesity, BMI 35+.

   1 site in Rhode Island

   • Clinical Res Collaborative, Cumberland

7. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

   Phase 2. Run by Novo Nordisk A/S. Registry number NCT07639021.

   A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

   Who can join. Adults 18+, have obesity, BMI 30+.

   1 site in Rhode Island

   • Clinical Res Collaborative, Cumberland

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact